Tìm theo
Daclizumab
Các tên gọi khác (3) :
  • Anti-IL-2
  • Humanized antiCD25
  • Ig gamma-1 chain C region
Thuốc giảm miễn dịch
Thuốc Gốc
Biotech
CAS: 152923-56-3
ATC: L04AC01
ĐG : F Hoffmann La Roche Ltd. , http://www.roche.com
CTHH: C6332H9808N1678O1989S42
PTK: 142612.1000
Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody.
Nhận Dạng Quốc Tế & Đặc Tính Hóa Học
Công thức hóa học
C6332H9808N1678O1989S42
Phân tử khối
142612.1000
Độ tan chảy
61 °C (FAB fragment), 71 °C (whole mAb)
Độ kỵ nước
-0.437
Điểm đẳng điện tích
8.46
Dược Lực Học : Zenapax functions as an IL-2 receptor antagonist. Specifically it inhibits IL-2-mediated activation of lymphocytes, a critical pathway in the cellular immune response involved in allograft rejection.
Cơ Chế Tác Dụng : Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. The murine sequences were derived from the complementarity-determining regions of a murine anti-Tac antibody. Zenepax binds with high-affinity to the Tac subunit of the high-affinity IL-2 receptor complex and inhibits IL-2 binding. The IL-2 receptor (Tac) subunit is expressed on activated but not resting lymphocytes.
Dược Động Học :

▧ Metabolism :
Most likely removed by opsonization via the reticuloendothelial system when bound to lymphocytes.
▧ Half Life :
11-38 days
Chỉ Định : Zenapax is a humanized monoclonal antibody used for prevention of renal transplant rejection
Tương Tác Thuốc :
  • Rilonacept results in increased immunosuppressive effects; increases the risk of infection.
  • Trastuzumab Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events.
Liều Lượng & Cách Dùng : Liquid - Intravenous
Dữ Kiện Thương Mại
Nhà Sản Xuất
Đóng gói
Tài Liệu Tham Khảo Thêm
drugbank
http://www.drugbank.ca/drugs/DB00111
GenBank
http://www.ncbi.nlm.nih.gov/nuccore/J00228
PharmGKB
http://www.pharmgkb.org/drug/PA164764446
Wikipedia
http://en.wikipedia.org/wiki/Daclizumab
RxList
http://www.rxlist.com/cgi/generic3/zenapax.htm
Drugs.com
http://www.drugs.com/cdi/daclizumab.html
... loading
... loading